Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Medicover AB ( ($SE:MCOV.B) ) is now available.
Medicover AB announced additional interim results from the DART clinical study at Oslo University Hospital, highlighting the effectiveness of its MRD assay in predicting disease progression in non-small cell lung cancer. The study, presented at the European Society for Medical Oncology Congress, strengthens the clinical validation of Medicover’s MRD assay, marking a significant step towards its commercialisation in 2026 and expansion into other therapeutic areas.
The most recent analyst rating on ($SE:MCOV.B) stock is a Hold with a SEK267.00 price target. To see the full list of analyst forecasts on Medicover AB stock, see the SE:MCOV.B Stock Forecast page.
More about Medicover AB
Medicover is a leading international healthcare and diagnostic services company founded in 1995. It operates a large number of ambulatory clinics, hospitals, laboratories, and blood-drawing points, with major markets in Poland, Germany, Romania, and India. In 2024, Medicover reported revenue of EUR 2,092 million and employed over 47,000 people.
Average Trading Volume: 71,737
Technical Sentiment Signal: Buy
Current Market Cap: SEK38.73B
See more data about MCOV.B stock on TipRanks’ Stock Analysis page.